IMG-004 was well tolerated across once daily (QD) doses ranging 50 mg to 300 mg for 10 days. Key liver function parameters remained within the normal reference range for all tested doses. No reports...
IMG-007, the only clinical-stage nondepleting anti-OX40 monoclonal antibody (mAb), is being evaluated in adult patients with alopecia areata (AA) and atopic dermatitis (AD).The enrollment of the Phase...
Treatment with IMG-007, the only clinical-stage nondepleting anti-OX40 monoclonal antibody (mAb), led to rapid, marked, and durable improvement of skin signs in patients with atopic dermatitis...
Inmagene Exercises Option to Obtain Worldwide License for IMG-007 and IMG-004
SAN DIEGO, Sept. 21, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals (Inmagene), a clinical-stage biotech company developing innovative and differentiated therapies for immunological and inflammatory diseases, today announced its partnership with Aditum Bio to create Celexor Bio (Celexor), a new biotech company focused on cell depletion of pathologic cells in autoimmune and inflammatory disorders. Celexor has been formed based on Inmagene's IMG-018, a pDC depleting antibody targeting immunoglobulin-like transcript 7 (ILT7). Celexor will obtain the exclusive global rights to develop, manufacture, and commercialize IMG-018, which will be renamed CLXR-901, in a transaction anticipated to close later this month.
Inmagene Biopharmaceuticals has reported positive topline data from a Phase I study of IMG-004, being developed to potentially treat immunological diseases.